PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol
DOI: 10.1055/s-0045-1805091
Original Article

Can 18F-FDG PET/CT Metabolic Tumor Volume Contribute to Better Prognostication in Pediatric Hodgkin's Lymphoma?

Sangeetha Ramdas
1   Pediatric Hematology-Oncology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
,
Saumya Sara Sunny
2   Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India
,
Hema Nalapalu Srinivasan
1   Pediatric Hematology-Oncology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
,
Rikki Rorima John
1   Pediatric Hematology-Oncology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
,
Rajeev Zachariah Kompithra
3   Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
,
Mahasampath Gowri
4   Department of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India
,
Leenu Lizbeth Joseph
1   Pediatric Hematology-Oncology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
,
Julie Hepzibah
2   Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India
,
Leni Grace Mathew
1   Pediatric Hematology-Oncology, Department of Pediatrics, Christian Medical College, Vellore, Tamil Nadu, India
› Institutsangaben Funding This study was funded by the Christian Medical College, Fluid Research Grant.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction

Studies in adults have shown that metabolic tumor volume (MTV) in fluorine-18 fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) is a strong predictor of event-free survival (EFS) and overall survival (OS) in Hodgkin's lymphoma, often outperforming clinical scores and molecular predictors. However, there very few studies on pediatric Hodgkin's lymphoma (PHL), with conflicting results.

Objectives

This retrospective study was conducted to evaluate the feasibility of MTV assessment in PHL and to assess its prognostic role, given the paucity of data from the developing world and the technical expertise required.

Materials and Methods

Children with PHL, treated per EuroNet-PHL-C1 interim guidelines/C2 protocol at our center from 2017 to 2020 who had baseline and interim PET (iPET) scan done at our institution were included. MTV was measured in tumor areas with standardized uptake value (SUVmax) ≥2.5. MTV and SUVmax were compared at diagnosis and after two chemotherapy courses.

Results

Sixty-one children (male:female = 1.5:1; mean age: 10.10 years) were recruited and categorized into four stages (SI: 11; SII: 15; SIII: 21; and SIV: 14) and three treatment groups (TG1: 16; TG2: 11; and TG3: 34). Based on iPET, 47 and 14 children were adequate and inadequate responders, respectively. At a median follow-up period of 54 months, the OS was 96.7% and the EFS was 85.2%. The median SUVmax and MTV were both found to increase with advancing disease stage with a positive correlation (r = 0.41; p = 0.002). The difference in the median MTV was statistically significant for SII versus SIII (p = 0.004) but not for the median SUVmax (p = 0.13). Similarly, the difference in the median MTV was statistically significant for TG2 versus TG3 (p = 0.001) but not for the median SUVmax (p = 0.06). The median MTV in baseline PET/CT with Deauville score–based treatment response groups for adequate and inadequate responders was 98.35 (37.93–298.2) mL and 145 (84.43–463.5) mL, respectively (p = 0.31), and for those with events versus no events, the median MTV was 304 (30.45–452.7) mL and 105.35 (37.9–309.2) mL, respectively (p = 0.82).

Conclusion

Baseline PET/CT MTV showed better correlation than SUVmax in delineating stage and treatment groups. However, MTV in isolation was not sensitive or specific enough in prognosticating treatment response or EFS (relapse or death) in this study setting. The addition of significant clinico-biochemical parameters with MTV for future studies could enhance prognostication.

Keywords

18F-FDG PET/CT - event-free survival - metabolic tumor volume - overall survival - pediatric Hodgkin's lymphoma - prognostication - standardized uptake value

Authors' Contributions

S.R. and S.S.S. contributed to the design of the study, literature search, clinical studies, data acquisition and analysis, and manuscript preparation. H.N.S. contributed to the concepts, literature search, clinical studies, data analysis, and manuscript editing. R.R.J. contributed to the concepts, design, literature search, clinical studies, data analysis, manuscript editing, and manuscript review. R.Z.K. contributed to the design, literature search, clinical studies, data analysis, and manuscript editing. M.G. contributed to the design, data analysis, statistical analysis, and manuscript editing. L.L.J. contributed to the concepts, design, literature search, clinical studies, data analysis, statistical analysis, and manuscript review. J.H. contributed to the concepts, design, literature search, clinical studies, statistical analysis, and manuscript review. L.G.M. contributed to the concepts, design, definition of intellectual content, literature search, clinical studies, statistical analysis, and manuscript review, and served as a guarantor.


The authors wish to state that the manuscript has been read and approved by all the authors, that the requirements for authorship have been met, and that each author believes that the manuscript represents honest work.


Patient Consent

Individual patient consent was not required for this retrospective study, as approved by the Institutional Review Board (IRB) of the institution (IRB Min No. 14743/6.7.22).




Publikationsverlauf

Artikel online veröffentlicht:
10. März 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin's lymphoma. Ann Oncol 2002; 13 (Suppl. 04) 147-152
    CrossrefPubMedSuche in Google Scholar
  • 2 Macfarlane GJ, Evstifeeva T, Boyle P, Grufferman S. International patterns in the occurrence of Hodgkin's disease in children and young adult males. Int J Cancer 1995; 61 (02) 165-169
    CrossrefPubMedSuche in Google Scholar
  • 3 PDQ Pediatric Treatment Editorial Board. Childhood Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries. National Cancer Institute (US); 2002. Accessed July 11, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK65726/
  • 4 Arya LS. Current strategies in the treatment of childhood Hodgkin's disease. Accessed July 11, 2024 at: https://www.indianpediatrics.net/nov2005/nov-1115-1128.HTM
  • 5 Mahajan A, Singh M, Bakhshi S. et al. Treating early-stage Hodgkin lymphoma in resource-limited settings: InPOG-HL-15-01 experience. Pediatr Blood Cancer 2021; 68 (10) e29219
    CrossrefPubMedSuche in Google Scholar
  • 6 Jain S, Bakhshi S, Seth R. et al. Risk based and response adapted radiation therapy for children and adolescents with newly diagnosed advanced stage Hodgkin lymphoma treated with ABVD chemotherapy: a report from the Indian pediatric oncology group study InPOG-HL-15-01. Leuk Lymphoma 2022; 63 (05) 1111-1118
    CrossrefPubMedSuche in Google Scholar
  • 7 Schwartz CL, Constine LS, Villaluna D. et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114 (10) 2051-2059
    CrossrefPubMedSuche in Google Scholar
  • 8 Daw S, Hasenclever D, Mascarin M. et al. Risk and response adapted treatment guidelines for managing first relapsed and refractory classical Hodgkin lymphoma in children and young people. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere 2020; 4 (01) e329
    CrossrefPubMedSuche in Google Scholar
  • 9 Kahn JM, Mauz-Korholz C, Hernandez T, Milgrom SA, Castellino SM. Pediatric and adolescent Hodgkin lymphoma: paving the way for standards of care and shared decision making. Am Soc Clin Oncol Educ Book 2024; 44 (03) e432420
    CrossrefPubMedSuche in Google Scholar
  • 10 National Cancer Institute. Childhood Hodgkin Lymphoma Treatment. PDQ. NCI. 2024. Accessed July 11, 2024 at: https://www.cancer.gov/types/lymphoma/hp/child-hodgkin-treatment-pdq
  • 11 Ansell SM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2022; 97 (11) 1478-1488
    CrossrefPubMedSuche in Google Scholar
  • 12 Meignan M, Cottereau AS, Specht L, Mikhaeel NG. Total tumor burden in lymphoma: an evolving strong prognostic parameter. Br J Radiol 2021; 94 (1127): 20210448
    CrossrefPubMedSuche in Google Scholar
  • 13 Kido H, Kato S, Funahashi K. et al. The metabolic parameters based on volume in PET/CT are associated with clinicopathological N stage of colorectal cancer and can predict prognosis. EJNMMI Res 2021; 11 (01) 87
    CrossrefPubMedSuche in Google Scholar
  • 14 Im HJ, Bradshaw T, Solaiyappan M, Cho SY. Current methods to define metabolic tumor volume in positron emission tomography: which one is better?. Nucl Med Mol Imaging 2018; 52 (01) 5-15
    CrossrefPubMedSuche in Google Scholar
  • 15 Mathew B, Vijayasekharan K, Shah S. et al. Prognostic value of 18F-FDG PET/CT-metabolic parameters at baseline and interim assessment in pediatric anaplastic large cell lymphoma. Clin Nucl Med 2020; 45 (03) 182-186
    CrossrefPubMedSuche in Google Scholar
  • 16 Chen S, He K, Feng F. et al. Metabolic tumor burden on baseline 18F-FDG PET/CT improves risk stratification in pediatric patients with mature B-cell lymphoma. Eur J Nucl Med Mol Imaging 2019; 46 (09) 1830-1839
    CrossrefPubMedSuche in Google Scholar
  • 17 Yang J, Yan J, Li J, Zhang H, Zhao Q, Xu W. Prognostic value of metabolic parameters in baseline 18F-FDG PET/CT for pediatric lymphoblastic lymphoma. Eur J Nucl Med Mol Imaging 2024; 51 (07) 1955-1964
    CrossrefPubMedSuche in Google Scholar
  • 18 Cottereau AS, Versari A, Loft A. et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 2018; 131 (13) 1456-1463
    CrossrefPubMedSuche in Google Scholar
  • 19 Milgrom SA, Kim J, Chirindel A. et al. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr Blood Cancer 2021; 68 (09) e29212
    CrossrefPubMedSuche in Google Scholar
  • 20 Reed JD, Masenge A, Buchner A. et al. The utility of metabolic parameters on baseline F-18 FDG PET/CT in predicting treatment response and survival in paediatric and adolescent Hodgkin lymphoma. J Clin Med 2021; 10 (24) 5979
    CrossrefPubMedSuche in Google Scholar
  • 21 Hirata K, Tamaki N. Quantitative FDG PET assessment for oncology therapy. Cancers (Basel) 2021; 13 (04) 869
    CrossrefPubMedSuche in Google Scholar
  • 22 Weiss GJ, Korn RL. Interpretation of PET scans: do not take SUVs at face value. J Thorac Oncol 2012; 7 (12) 1744-1746
    CrossrefPubMedSuche in Google Scholar
  • 23 PDQ Pediatric Treatment Editorial Board. Childhood Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002 [cited 2025 Feb 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK65726/
  • 24 John JR, Oommen R, Hephzibah J. et al. Validation of Deauville score for response evaluation in Hodgkin's lymphoma. Indian J Nucl Med 2023; 38 (01) 16-22
    CrossrefPubMedSuche in Google Scholar
  • 25 Rogasch JMM, Hundsdoerfer P, Hofheinz F. et al. Pretherapeutic FDG-PET total metabolic tumor volume predicts response to induction therapy in pediatric Hodgkin's lymphoma. BMC Cancer 2018; 18 (01) 521
    CrossrefPubMedSuche in Google Scholar
  • 26 Weisman AJ, Kim J, Lee I. et al. Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients. EJNMMI Phys 2020; 7 (01) 76
    CrossrefPubMedSuche in Google Scholar
  • 27 Mauz-Körholz C, Landman-Parker J, Balwierz W. et al. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol 2022; 23 (01) 125-137
    CrossrefPubMedSuche in Google Scholar
  • 28 Mauz-Körholz C, Hasenclever D, Dörffel W. et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28 (23) 3680-3686
    CrossrefPubMedSuche in Google Scholar
  • 29 Radhakrishnan V, Kapoor G, Arora B, Bansal D, Vora T, Prasad M. et al. Management of Hodgkins Lymphoma: ICMR Consensus Document. Indian J Pediatr 2017; 84 (05) 371-381
    CrossrefPubMedSuche in Google Scholar
  • 30 Zhou Y, Hong Z, Zhou M. et al. Prognostic value of baseline 18 F-FDG PET/CT metabolic parameters in paediatric lymphoma. J Med Imaging Radiat Oncol 2020; 64 (01) 87-95
    CrossrefPubMedSuche in Google Scholar
  • 31 Lopci E, Mascarin M. Role of volumetric analyses on [18F]FDG PET/CT in pediatric Hodgkin lymphoma. Expert Rev Hematol 2023; 16 (09) 629-631
    CrossrefPubMedSuche in Google Scholar
  • 32 Cao Y, Zhou K, Diao W. et al. Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects. Quant Imaging Med Surg 2021; 11 (01) 95-106
    CrossrefPubMedSuche in Google Scholar
  • 33 Parekh A, Keller FG, McCarten KM. et al. Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood 2022; 140 (10) 1086-1093
    CrossrefPubMedSuche in Google Scholar
  • 34 Al-Ibraheem A, Anwer F, Juweid ME. et al. Interim FDG-PET/CT for therapy monitoring and prognostication in Hodgkin's lymphoma. Sci Rep 2022; 12 (01) 17702
    CrossrefPubMedSuche in Google Scholar
  • 35 Schwartz CL, Chen L, McCarten K. et al. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2017; 64 (04) e26278
    CrossrefPubMedSuche in Google Scholar